ArticleFrontiers in genetics2025
RPMB predicts the disease-free survival of head-and-neck squamous carcinoma after adjuvant concurrent radio-chemotherapy.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Currently, adjuvant concurrent radio-chemotherapy (ACRT) is the standard of care for head-and-neck squamous cell carcinoma (HNSC) with microscopically involved surgical margins (MISM) and/or extra-nodal extension (ENE), whereas the toxicity of cisplatin-based chemotherapy is non-negligible. Methods: In the current study, we identified a novel biomarker, referred to as RPMB (Repair Gene Promoter Methylation Burden), with the aim of identifying the subset of HNSC patients who are likely to respond favorably to ACRT. RPMB is defined as the proportion of methylated DNA repair genes (DRGs) relative to the total number of DRGs. We obtained the methylation profiles and clinical data for 528 HNSC patients from the Cancer Genome Atlas (TCGA) database. Results: Analysis revealed that the DRGs in HNSC were significantly hypomethylated compared to the other genes across the entire methylation profile (all Conclusion: Low RPMB might serve as a promising indicator for identifying suitable HNSC patients who might be medically fit for ACRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.